Cencora gears up to report Q4 results: How to play the stock?
Cencora, Inc. COR is slated to report fourth-quarter fiscal 2026 results on Nov. 4, before market open. In the last reported ...
Model output · Signal date 2026-11-06
Cencora, Inc. (COR) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
-8.0%
Spearman, 357 dates
Market Cap
$63.65B
large-cap · #2 of 7 peers
Summary
Cencora, Inc. (COR) stock forecast summary
Our AI scores Cencora, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Cencora, Inc. is a large-cap company with a market capitalization of $63.65B. It ranks number 2 by market capitalization among the 7 Wholesale-Drugs, Proprietaries & Druggists' Sundries issuers in our coverage with a current forecast.
For COR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -8.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -6.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, COR included.
Price
COR price chart and AI forecast
Cross-section · 2026-11-06
How COR ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Cencora, Inc. (COR) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Wholesale-Drugs, Proprietaries & Druggists' Sundries peers listed below that report each metric.
Valuation & Market
| Metric | COR | Rank |
|---|---|---|
| Market Cap | $63.65B | 2/7 |
| P/E Ratio | 24.76x | – |
| P/B Ratio | 20.86x | – |
| Dividend Yield | 0.74% | – |
| EPS | $13.47 | – |
| Book Value/Share | $15.99 | – |
| Revenue/Share | $1743.84 | – |
| FCF/Share | $21.28 | – |
Profitability & Margins
| Metric | COR | Rank |
|---|---|---|
| ROE | 86.0% | – |
| ROA | 3.1% | 3/6 |
| ROIC | 12.4% | 3/5 |
| Gross Margin | 4.0% | 5/7 |
| Operating Margin | 0.9% | 3/6 |
| Net Margin | 0.8% | 3/7 |
| EBT Margin | 1.1% | 3/7 |
| Tax Rate | 26.8% | – |
Financial Health
| Metric | COR | Rank |
|---|---|---|
| Current Ratio | 0.93x | 5/7 |
| Quick Ratio | 0.58x | 5/7 |
| D/E Ratio | 26.41x | – |
| Financial Leverage | 27.47x | – |
| Interest Coverage | 0.1x | 5/6 |
| Working Capital | -$3.86B | 5/7 |
Cash Flow
| Metric | COR | Rank |
|---|---|---|
| Operating Cash Flow | $4.82B | 3/7 |
| Free Cash Flow | $4.06B | 2/5 |
| Capital Spending | -$761M | 5/5 |
| OCF Growth YoY | 176.7% | 1/5 |
| FCF Growth YoY | 255.7% | – |
| FCF/Sales | 1.2% | 3/5 |
| CapEx/Sales | 0.2% | 4/5 |
Operational Efficiency
| Metric | COR | Rank |
|---|---|---|
| Asset Turnover | 3.97x | 2/5 |
| Receivables Turnover | 13.1x | 5/5 |
| Inventory Turnover | 15.2x | 3/7 |
| Fixed Assets Turnover | 117.2x | 2/5 |
| Days Sales Outstanding | 28 days | 1/5 |
| Days Inventory | 24 days | 5/7 |
| Payables Period | 62 days | 2/6 |
| Cash Conversion Cycle | -11 days | – |
Income Statement
| Metric | COR | Rank |
|---|---|---|
| Total Revenue | $332.77B | 2/5 |
| Operating Income | $3.04B | 3/6 |
| Net Income | $2.62B | 3/7 |
| SG&A Expense | $7.65B | 3/6 |
| Cost of Goods Sold | $319.55B | 2/7 |
Dividend & Shareholder Information
| Metric | COR | Rank |
|---|---|---|
| Dividends Per Share | $2.45 | – |
| Payout Ratio | 18.2% | – |
| Shares Outstanding | 191M | – |
| Net Income Growth | 38.4% | 2/5 |
| EPS Growth | 38.3% | 2/5 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $55.34B | 66.0% of assets |
| Cash & Short-term Investments | $2.82B | 3.4% of assets |
| Accounts Receivable | $25.45B | 30.4% of assets |
| Inventory | $21.03B | 25.1% of assets |
| Total Liabilities | $80.57B | 96.1% of assets |
| Short-term Debt | $4.50B | 5.4% of assets |
Quarterly Financial Reports
COR quarterly financials and insider trading
Industry Peers · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Cencora, Inc. (COR) industry peers
Companies classified under the same SEC industry code as Cencora, Inc. (Wholesale-Drugs, Proprietaries & Druggists' Sundries): 7 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere COR sits on the market map
Trade & Services · Wholesale-Drugs, Proprietaries & Druggists' Sundries
News
Cencora, Inc. (COR) stock news
Cencora to acquire Aon in $2.4B deal to expand oncology network
Cencora, Inc. COR recently announced a definitive agreement to acquire American Oncology Network (“AON”), a physician-led ...
Cencora Earnings Call Highlights Specialty Growth and Headwinds
((COR)) has held its Q4 earnings call. Read on for the main highlights of the call. Cencora’s earnings call carried a broadly positive tone, led by record fiscal 2026 results, strong fourth-quarter ...
FAQ
Cencora, Inc. (COR) stock forecast FAQ
What is the Cencora, Inc. (COR) stock forecast?
Our AI scores Cencora, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Cencora, Inc. stock predictions?
For COR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -8.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -6.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Cencora, Inc. forecasts updated?
Cencora, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Cencora, Inc.'s industry peers?
7 issuers in our coverage, COR included, share the SEC industry code Wholesale-Drugs, Proprietaries & Druggists' Sundries. The largest are: Mckesson Corp (MCK), Cardinal Health Inc (CAH), Herbalife Ltd. (HLF), Nu Skin Enterprises, Inc. (NUS), Enersyn Global Inc. (ESYN), Cosmos Health Inc. (COSM).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.